HCPCS code J9347 — Inj, tremelimumab-actl, 1 mg. Status: Active. Effective Jul 1, 2023. Source: CMS HCPCS Level II.

J9347

Active

Inj, tremelimumab-actl, 1 mg

Injection, tremelimumab-actl, 1 mg

Category: Drugs
Section: J-codes: Drugs Administered Other Than Oral Method
Effective: Jul 1, 2023
Code type: alphanumeric
OPPS Status: K — Non-pass-through drugs and biologicals
OPPS APC: 9110

MUE — Medically Unlikely Edits

Maximum units of J9347 Medicare will pay for one beneficiary on one date of service. Claims exceeding the MUE are denied or returned for review.

Service Type Max Units / Day
Outpatient Hospital 300
Practitioner Services 300

Source: CMS Medicare NCCI Medically Unlikely Edits

NDC Crosswalk

National Drug Codes (NDCs) mapped to this HCPCS code.

NDC Drug Name
00310-4505-25 Imjudo
00310-4535-30 Imjudo

Change History

Quarterly changes published by CMS. Revisions may affect the code description, coverage, or rate — review each quarter's changes before submitting claims.

  • New Code 2023-Q3
    Inj, tremelimumab-actl, 1 mg